دورية أكاديمية
أعرض في EDS

Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.

التفاصيل البيبلوغرافية
العنوان: Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
المؤلفون: Vemulapalli HS; Cardiology, Mayo Clinic, Phoenix, USA., Vajje J; Internal Medicine, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, Vijayawada, IND., Rehman W; Internal Medicine, United Health Services Hospitals, State University of New York Upstate Medical University Binghamton Campus, Johnson City, USA., Virk GS; Internal Medicine, Avalon University School of Medicine, Ohio, USA., Shah K; Internal Medicine, Gujarat Medical Education and Research Society (GMERS) Medical College, Gandhinagar, IND., Chaudhari SS; General Physician, Lions General Hospital, Mehsana, IND.; General Practice, General Hospital, Vadnagar, IND., Mian IU; Medicine, Combined Military Hospital (CMH) Lahore Medical College and Institute of Dentistry, Lahore, PAK., Saleem F; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.; Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore, PAK.
المصدر: Cureus [Cureus] 2023 Sep 17; Vol. 15 (9), pp. e45421. Date of Electronic Publication: 2023 Sep 17 (Print Publication: 2023).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Diabetes mellitus (DM) is a chronic metabolic disorder, with type 2 diabetes (T2DM) significantly impacting the cardiovascular (CV) system. Our comprehensive study on the cardiovascular effects of liraglutide, conducted concurrently with the formulation of diabetes treatment guidelines, aims to provide healthcare providers and patients with reassurance regarding the safety and effectiveness of liraglutide. From the beginning until August 20, 2023, we conducted searches in databases including PubMed, Web of Science, Embase, Cochrane Library, Scopus, and Google Scholar. These searches aimed to identify studies comparing liraglutide to control in terms of symptom resolution among patients with T2DM. For all relevant outcomes, we calculated risk ratios along with their corresponding 95% confidence intervals. Thirteen randomized controlled trials (RCTs) were included in this analysis. The results demonstrated a significant reduction in the risk of major adverse cardiovascular events (MACE), myocardial infarction, CV mortality, and all-cause mortality. No significant difference was found between the liraglutide and control groups for the outcome of stroke. However, sensitivity analysis revealed a significant reduction in the risk of stroke among patients taking liraglutide. Our comprehensive meta-analysis strongly supports the use of liraglutide for managing cardiovascular disease (CVD) due to its established safety and effectiveness. Further RCTs and meta-analyses are needed to more thoroughly evaluate liraglutide's therapeutic potential, with the aim of enhancing the quality of life for those with CVD.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Vemulapalli et al.)
References: Lancet. 2005 Apr 9-15;365(9467):1333-46. (PMID: 15823385)
BMC Endocr Disord. 2022 May 12;22(1):125. (PMID: 35546664)
Lancet Diabetes Endocrinol. 2015 Sep;3(9):697-703. (PMID: 26276240)
Lancet. 2007 Sep 29;370(9593):1129-36. (PMID: 17905165)
Expert Rev Cardiovasc Ther. 2015;13(7):753-67. (PMID: 26106933)
Ann Intern Med. 2004 Sep 21;141(6):413-20. (PMID: 15381514)
Lancet. 2010 Apr 24;375(9724):1447-56. (PMID: 20417856)
N Engl J Med. 2007 Jun 14;356(24):2457-71. (PMID: 17517853)
Endocrine. 2014 Dec;47(3):962-4. (PMID: 24696097)
Circulation. 2018 Dec 18;138(25):2908-2918. (PMID: 30566006)
N Engl J Med. 2018 Aug 16;379(7):633-644. (PMID: 30110583)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Diabetologia. 2009 Oct;52(10):2046-55. (PMID: 19688338)
Can J Diabetes. 2017 Oct;41(5):524-535. (PMID: 28942790)
Br J Pharmacol. 2009 Aug;157(8):1340-51. (PMID: 19681866)
Diab Vasc Dis Res. 2018 Sep;15(5):465-468. (PMID: 29947247)
Ann Intern Med. 2019 Mar 19;170(6):423-426. (PMID: 30508430)
Medicine (Baltimore). 2019 Nov;98(46):e17860. (PMID: 31725627)
Diabet Med. 2009 Mar;26(3):268-78. (PMID: 19317822)
Cardiovasc Diabetol. 2021 Sep 15;20(1):189. (PMID: 34526024)
J Pharmacol Exp Ther. 2006 Jun;317(3):1106-13. (PMID: 16489128)
Nat Rev Cardiol. 2012 Jan 31;9(4):209-22. (PMID: 22290234)
J Am Coll Cardiol. 2020 Mar 17;75(10):1128-1141. (PMID: 32164886)
Diabetes Obes Metab. 2017 Jun;19(6):901-905. (PMID: 28105731)
Diabetes Care. 2009 Jan;32(1):84-90. (PMID: 18931095)
Circulation. 2018 Dec 18;138(25):2884-2894. (PMID: 30566004)
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. (PMID: 29221659)
BMJ Open. 2013 Jan 24;3(1):. (PMID: 23355666)
J Clin Endocrinol Metab. 1986 Aug;63(2):492-8. (PMID: 3522621)
Am Heart J. 2010 Apr;159(4):612-619.e3. (PMID: 20362720)
Lancet. 2009 May 23;373(9677):1765-72. (PMID: 19465231)
Curr Med Res Opin. 2010 May;26(5):1013-22. (PMID: 20199137)
Endocrine. 2014 Sep;47(1):21-8. (PMID: 24493030)
N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
BMJ. 2011 Oct 18;343:d5928. (PMID: 22008217)
Heart. 2011 Jan;97(1):6-14. (PMID: 21106556)
Prog Cardiovasc Dis. 2009 Jul-Aug;52(1):6-10. (PMID: 19615487)
J Clin Invest. 1999 Sep;104(6):787-94. (PMID: 10491414)
Diabetes Obes Metab. 2011 Apr;13(4):348-56. (PMID: 21205128)
Am J Public Health. 2016 Dec;106(12):2113-2125. (PMID: 27736219)
Lancet Diabetes Endocrinol. 2018 Feb;6(2):130-142. (PMID: 28970034)
Adv Ther. 2014 Nov;31(11):1182-95. (PMID: 25388240)
Diabetes Care. 2009 Jul;32(7):1224-30. (PMID: 19289857)
فهرسة مساهمة: Keywords: cardiovascular outcomes; diabetes mellitus; efficacy; liraglutide; meta-analysis; patients; randomized controlled trials; safety
تواريخ الأحداث: Date Created: 20231019 Latest Revision: 20231020
رمز التحديث: 20231020
مُعرف محوري في PubMed: PMC10581595
DOI: 10.7759/cureus.45421
PMID: 37854744
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.45421